Kochaksaraei Golasa Samadi, Yang Fengjuan, Seow Cynthia H, Barkema Herman W, Coffin Carla S, Shaheen Abdel-Aziz
Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Ann Hepatol. 2024 Sep 17;30(1):101576. doi: 10.1016/j.aohep.2024.101576.
There are limited recent data on the burden of chronic hepatitis B (CHB) in the North American general population. We aimed to identify the CHB burden from a Canadian population-based perspective.
Using a retrospective cohort design, we searched Alberta Analytics administrative databases including the Provincial Laboratory database, to describe CHB epidemiology and natural history in Alberta, Canada between fiscal years 2012-2020. We analyzed incidence and prevalence trends using a Poisson regression model and conducted Kaplan-Meier analyses to examine the incident cohort's survival.
The age/sex-adjusted incidence of CHB between 2015-2020 was 27.1/100,000 person/years (29.6/100,000 in males and 24.5/100,000 in females) and was highest among individuals aged 45-64 years. Despite a decrease in annual incidence of CHB from 36.4 to 13.4/100,000 between 2015-2020, prevalence increased from 98.9 to 210.3/100,000 in the same period. Of 6,860 incident cases, 2.1% died, and 0.2% underwent liver transplantation during a median follow-up of 3.6 years (interquartile range 2.0-4.9 years). CHB patients had significantly lower survival rates compared to age/sex-matched Canadians, with a standardized mortality ratio of 3.9 (95% confidence interval [CI] 3.3-4.6). Male sex (hazard ratio [HR] 1.7; 95% CI 1.2-2.5), older age at diagnosis (HR, 1.08; 95% CI 1.07-1.09) independently predicted mortality.
CHB incidence decreased in Alberta, which is consistent with nationwide trends. Males and individuals aged 45-64 had higher CHB incidence and prevalence. CHB patients' lower survival rates emphasize the need to address barriers to guideline recommended HBV care linkage.
北美普通人群中慢性乙型肝炎(CHB)负担的近期数据有限。我们旨在从加拿大基于人群的角度确定CHB负担。
采用回顾性队列设计,我们检索了艾伯塔分析管理数据库,包括省级实验室数据库,以描述2012 - 2020财年加拿大艾伯塔省CHB的流行病学和自然史。我们使用泊松回归模型分析发病率和患病率趋势,并进行Kaplan - Meier分析以检查发病队列的生存率。
2015 - 2020年间,CHB的年龄/性别调整发病率为27.1/100,000人/年(男性为29.6/100,000,女性为24.5/100,000),在45 - 64岁人群中最高。尽管2015 - 2020年间CHB的年发病率从36.4降至13.4/100,000,但同期患病率从98.9升至210.3/100,000。在6860例发病病例中,2.1%死亡,在中位随访3.6年(四分位间距2.0 - 4.9年)期间,0.2%接受了肝移植。与年龄/性别匹配的加拿大人相比,CHB患者的生存率显著较低,标准化死亡比为3.9(95%置信区间[CI] 3.3 - 4.6)。男性(风险比[HR] 1.7;95% CI 1.2 - 2.5)、诊断时年龄较大(HR,1.08;95% CI 1.07 - 1.09)独立预测死亡率。
艾伯塔省CHB发病率下降,这与全国趋势一致。男性和45 - 64岁个体的CHB发病率和患病率较高。CHB患者较低的生存率强调了消除指南推荐的乙肝护理联系障碍的必要性。